« Back
Home /
Asnuciclib

Asnuciclib

Manufacturer	MedChem Express
Category	Oncology Neuroscience Neuroinflammation Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Heart & Blood Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Amount	5 mg
Item no.	HY-12445-5mg
Targets	CDK; Apoptosis
CASRN	1421693-22-2
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Asnuciclib (CDKI-73; LS-007) is an orally active and highly efficacious CDK9 inhibitor, with Ki values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. Asnuciclib down-regulates the RNAPII phosphorylation. Asnuciclib is also a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion[1][2][3][4].
StorageTemperature	4°C (Powder, stored under nitrogen)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	394.45
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer; Inflammation/Immunology
Solubility	DMSO : ≥ 52 mg/mL
Manufacturers Target	Apoptosis; CDK
Isoform	CDK1; CDK2; CDK4; CDK6; CDK7; CDK9
Pathway	Apoptosis; Cell Cycle/DNA Damage
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12445-5mg-safety-datasheet.pdf